In May 2023, HHS and DEA issued a temporary rule (First Temporary Rule) that extended these flexibilities until Nov. 11, 2023, for practitioner-patient relationships formed after the expiration of the COVID-19 PHE.

On June 30, 2023, the Centers for Medicare and Medicaid Services (CMS) issued final guidance on the Inflation Reduction Act (IRA) Medicare Drug Price Negotiation Program for the initial price applicability year 2026 (Revised Guidance).

On June 2, 2023, CMS issued a memo via HPMS reminding plan sponsors of requirements related to the pharmacy price concessions provisions in the May 9, 2022 final rule (CMS-4192- F).

On January 31, 2020, HHS declared a public health emergency (Declaration) pursuant to the Public Readiness and Emergency Preparedness Act (PREP Act), in response to the COVID– 19 outbreak.

The Substance Abuse and Mental Health Services Administration (SAMHSA) and the Drug Enforcement Administration (DEA) are issuing this temporary rule to extend certain exceptions granted to existing DEA regulations in March 2020 because of the COVID-19 Public Health Emergency (COVID-19 PHE).

On April 5, 2023, the Centers for Medicare and Medicaid Services (CMS) issued a Final Rule, titled “Medicare Program; Contract Year 2024 Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, Medicare Cost Plan Program, and Programs of All-Inclusive Care for the Elderly” (Final Rule).

Substance Abuse and Mental Health Services Administration (SAMHSA) within the Department of Health and Human Services (“HHS”) issued a final rule on Medications for the Treatment of Opioid Use Disorder (Final Rule), to be published on Feb. 2, 2024.